HAEMONETICS CORP/MASS (HAE)
US4050241003 - Common Stock
Overall HAE gets a fundamental rating of 6 out of 10. We evaluated HAE against 188 industry peers in the Health Care Equipment & Supplies industry. HAE scores excellent on profitability, but there are some minor concerns on its financial health. HAE is growing strongly while it is still valued neutral. This is a good combination! This makes HAE very considerable for growth investing!
1. Profitability
1.1 Basic Checks
HAE had positive earnings in the past year.
In the past year HAE had a positive cash flow from operations.
HAE had positive earnings in each of the past 5 years.
In the past 5 years HAE always reported a positive cash flow from operatings.
1.2 Ratios
HAE's Return On Assets of 4.90% is amongst the best of the industry. HAE outperforms 83.96% of its industry peers.
HAE's Return On Equity of 14.09% is amongst the best of the industry. HAE outperforms 89.30% of its industry peers.
The Return On Invested Capital of HAE (7.59%) is better than 86.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HAE is in line with the industry average of 8.23%.
The 3 year average ROIC (7.51%) for HAE is below the current ROIC(7.59%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.9% | ||
| ROE | 14.09% | ||
| ROIC | 7.59% |
ROA(3y)4.55%
ROA(5y)4.81%
ROE(3y)10.72%
ROE(5y)11.21%
ROIC(3y)7.51%
ROIC(5y)8.04%
1.3 Margins
The Profit Margin of HAE (9.10%) is better than 83.42% of its industry peers.
In the last couple of years the Profit Margin of HAE has grown nicely.
HAE has a better Operating Margin (15.80%) than 86.63% of its industry peers.
HAE's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 54.02%, HAE is in line with its industry, outperforming 45.99% of the companies in the same industry.
In the last couple of years the Gross Margin of HAE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.8% | ||
| PM (TTM) | 9.1% | ||
| GM | 54.02% |
OM growth 3Y24.43%
OM growth 5Y5.91%
PM growth 3Y-0.56%
PM growth 5Y9.58%
GM growth 3Y4.96%
GM growth 5Y3.61%
2. Health
2.1 Basic Checks
HAE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, HAE has more shares outstanding
HAE has less shares outstanding than it did 5 years ago.
The debt/assets ratio for HAE has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.90 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
HAE has a Altman-Z score of 2.90. This is in the better half of the industry: HAE outperforms 65.78% of its industry peers.
HAE has a debt to FCF ratio of 39.37. This is a negative value and a sign of low solvency as HAE would need 39.37 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 39.37, HAE is in the better half of the industry, outperforming 68.45% of the companies in the same industry.
HAE has a Debt/Equity ratio of 1.39. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HAE (1.39) is worse than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.39 | ||
| Debt/FCF | 39.37 | ||
| Altman-Z | 2.9 |
ROIC/WACC0.91
WACC8.37%
2.3 Liquidity
A Current Ratio of 3.49 indicates that HAE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.49, HAE is in line with its industry, outperforming 59.89% of the companies in the same industry.
A Quick Ratio of 2.09 indicates that HAE has no problem at all paying its short term obligations.
The Quick ratio of HAE (2.09) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.49 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.48% over the past year.
HAE shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.74% yearly.
The Revenue has grown by 9.85% in the past year. This is quite good.
Measured over the past years, HAE shows a small growth in Revenue. The Revenue has been growing by 6.23% on average per year.
EPS 1Y (TTM)11.48%
EPS 3Y19.2%
EPS 5Y10.74%
EPS Q2Q%13.13%
Revenue 1Y (TTM)9.85%
Revenue growth 3Y14.57%
Revenue growth 5Y6.23%
Sales Q2Q%8.59%
3.2 Future
HAE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.40% yearly.
The Revenue is expected to grow by 10.74% on average over the next years. This is quite good.
EPS Next Y16.44%
EPS Next 2Y16.25%
EPS Next 3Y16.79%
EPS Next 5Y21.4%
Revenue Next Year7.8%
Revenue Next 2Y6.34%
Revenue Next 3Y7.15%
Revenue Next 5Y10.74%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.94, the valuation of HAE can be described as rather expensive.
Based on the Price/Earnings ratio, HAE is valued cheaply inside the industry as 86.63% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of HAE to the average of the S&P500 Index (28.96), we can say HAE is valued slightly cheaper.
With a Price/Forward Earnings ratio of 15.88, HAE is valued correctly.
Based on the Price/Forward Earnings ratio, HAE is valued cheaply inside the industry as 88.77% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HAE to the average of the S&P500 Index (23.82), we can say HAE is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.94 | ||
| Fwd PE | 15.88 |
4.2 Price Multiples
84.49% of the companies in the same industry are more expensive than HAE, based on the Enterprise Value to EBITDA ratio.
68.98% of the companies in the same industry are more expensive than HAE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 137.89 | ||
| EV/EBITDA | 15.99 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of HAE may justify a higher PE ratio.
A more expensive valuation may be justified as HAE's earnings are expected to grow with 16.79% in the coming years.
PEG (NY)1.27
PEG (5Y)1.95
EPS Next 2Y16.25%
EPS Next 3Y16.79%
5. Dividend
5.1 Amount
No dividends for HAE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HAEMONETICS CORP/MASS
NYSE:HAE (11/21/2024, 8:04:00 PM)
After market: 85.43 0 (0%)85.43
+0.51 (+0.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.29B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.94 | ||
| Fwd PE | 15.88 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.27
PEG (5Y)1.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.9% | ||
| ROE | 14.09% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 15.8% | ||
| PM (TTM) | 9.1% | ||
| GM | 54.02% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.39 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.49 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)11.48%
EPS 3Y19.2%
EPS 5Y
EPS Q2Q%
EPS Next Y16.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.85%
Revenue growth 3Y14.57%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y